Cannabidiol (CBD) appears to slow the growth of glioblastoma brain cancer cells in both animal and human cell lines. CBD's anti-cancer actions target mitochondria, causing them to dysfunction and release harmful reactive oxygen species. Cancer cells treated with CBD exhibited significant decreases in mitochondrial activity.
Using purified botanical cannabidiol (CBD) to treat mouse models of Davet syndrome improved mortality and reduced behavioral symptoms associated with the condition.
Many cannabis users don't know how much THC or CBD is considered an effective dose.
Analyzing the results of 15 different studies involving over 300 subjects, researchers discovered a single dose of THC could induce psychiatric symptoms in people with no history of psychosis.
During memory tasks, people with psychosis have different patterns of activity in the prefrontal and mediotemporal brain areas compared to those without the disorder. When exposed to cannabidiol (CBD), the activity of the brain areas became more like those seen in the controls for people with psychosis. Patients reported a decrease in symptoms of psychosis following one dose of CBD. Researchers stress that no definitive conclusions could be made about the effectiveness of CBD use over a sustained period.
The effect cannabidiol has on Lennox-Gastaut syndrome may be explained by the drug-drug interaction between CBD and anti-seizure medication.
Brain and fetal development damage caused by exposure to CBD and THC are very similar defects seen in fetal alcohol syndrome.